Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Albiges, Laurence ; Powles, Tom ; Staehler, Michael ; Bensalah, Karim ; Giles, Rachel H. ; Hora, Milan ; Kuczyk, Markus A. ; Lam, Thomas B. ; Ljungberg, Börje and Marconi, Lorenzo , et al. (2019) In European Urology 76(2). p.151-156
Abstract

Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cabozantinib, Guidelines, Immune checkpoint inhibitors, Ipilimumab, Metastatic, Nivolumab, Pazopanib, Renal cell carcinoma, Sunitinib
in
European Urology
volume
76
issue
2
pages
151 - 156
publisher
Elsevier
external identifiers
  • pmid:31151678
  • scopus:85066081578
ISSN
0302-2838
DOI
10.1016/j.eururo.2019.05.022
language
English
LU publication?
yes
id
7191f91f-0a9d-4d99-8ee3-597450065620
date added to LUP
2019-06-18 07:20:52
date last changed
2022-05-11 18:35:58
@article{7191f91f-0a9d-4d99-8ee3-597450065620,
  abstract     = {{<p>Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.</p>}},
  author       = {{Albiges, Laurence and Powles, Tom and Staehler, Michael and Bensalah, Karim and Giles, Rachel H. and Hora, Milan and Kuczyk, Markus A. and Lam, Thomas B. and Ljungberg, Börje and Marconi, Lorenzo and Merseburger, Axel S. and Volpe, Alessandro and Abu-Ghanem, Yasmin and Dabestani, Saeed and Fernández-Pello, Sergio and Hofmann, Fabian and Kuusk, Teele and Tahbaz, Rana and Bex, Axel}},
  issn         = {{0302-2838}},
  keywords     = {{Cabozantinib; Guidelines; Immune checkpoint inhibitors; Ipilimumab; Metastatic; Nivolumab; Pazopanib; Renal cell carcinoma; Sunitinib}},
  language     = {{eng}},
  month        = {{05}},
  number       = {{2}},
  pages        = {{151--156}},
  publisher    = {{Elsevier}},
  series       = {{European Urology}},
  title        = {{Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma}},
  url          = {{http://dx.doi.org/10.1016/j.eururo.2019.05.022}},
  doi          = {{10.1016/j.eururo.2019.05.022}},
  volume       = {{76}},
  year         = {{2019}},
}